DeepMed Research

Pazopanib

Generic Name: Pazopanib

Brand Names: Votrient

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₃N_₇O_₂S

CAS Number: 444731-52-6

Unique Ingredient Identifier: 7RN5DR86CK

Background: Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication: Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions: Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer

Clinical Trials

Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: pazopanib hydrochloride
Other: laboratory biomarker analysis
Other: pharmacogenomic studies
Other: pharmacological study
Procedure: quality-of-life assessment

First Posted Date: 2010-09-23

Last Posted Date: 2018-07-12

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 102

Registration Number: NCT01208064

Locations: 🇩🇪
Klinik Loewenstein, Loewenstein, Germany
🇬🇷
University General Hospital Heraklion, Heraklion, Greece
🇩🇪
UniversitaetsMedizin Mannheim, Mannheim, Germany

and more 18 locations

VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK

Phase 4

Completed

Conditions: Cancer

Interventions: Drug: pazopanib

First Posted Date: 2010-09-20

Last Posted Date: 2012-05-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 34

Registration Number: NCT01205230

Locations: 🇺🇸
GSK Investigational Site, Greenville, South Carolina, United States

Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

Phase 1

Completed

Conditions: Solid Tumor
Kidney Cancer

Interventions: Drug: pazopanib
Drug: everolimus

First Posted Date: 2010-08-18

Last Posted Date: 2019-10-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT01184326

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pazopanib plus Paclitaxel

First Posted Date: 2010-08-11

Last Posted Date: 2016-10-12

Lead Sponsor: Loyola University

Registration Number: NCT01179269

Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Metastatic Cancer
Solid Tumors

Interventions: Drug: cisplatin
Drug: Pazopanib

First Posted Date: 2010-07-19

Last Posted Date: 2014-11-17

Lead Sponsor: UNICANCER

Target Recruit Count: 35

Registration Number: NCT01165385

Locations: 🇫🇷
Centre Georges François LECLERC, Dijon, France
🇫🇷
Institut Curie, Paris, France
🇫🇷
Centre Léon Berard, Lyon, France

and more 2 locations

Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer

Phase 2

Completed

Conditions: Stage II Renal Cell Cancer
Clear Cell Renal Cell Carcinoma
Stage I Renal Cell Cancer
Stage III Renal Cell Cancer

Interventions: Drug: pazopanib hydrochloride
Procedure: therapeutic conventional surgery

First Posted Date: 2010-07-08

Last Posted Date: 2018-09-12

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 25

Registration Number: NCT01158521

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer

Phase 2

Completed

Conditions: Stage IV Renal Cell Cancer
Clear Cell Renal Cell Carcinoma
Recurrent Renal Cell Cancer

Interventions: Drug: pazopanib hydrochloride
Other: laboratory biomarker analysis
Other: immunologic technique

First Posted Date: 2010-07-05

Last Posted Date: 2022-06-08

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 28

Registration Number: NCT01157091

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
South Pasadena Cancer Center, Pasadena, California, United States

A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration

Phase 1

Completed

Conditions: Macular Degeneration

Interventions: Drug: Pazopanib

First Posted Date: 2010-06-30

Last Posted Date: 2017-11-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 15

Registration Number: NCT01154062

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Phase 2

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Pazopanib
Drug: Sunitinib

First Posted Date: 2010-06-22

Last Posted Date: 2025-03-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 367

Registration Number: NCT01147822

Locations: 🇨🇳
Novartis Investigative Site, Taoyuan County, Taiwan

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

Phase 2

Completed

Conditions: Macular Degeneration

Interventions: Drug: pazopanib eye drops
Drug: placebo
Biological: ranibizumab intravitreal injection

First Posted Date: 2010-05-31

Last Posted Date: 2018-01-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 510

Registration Number: NCT01134055

Locations: 🇸🇪
GSK Investigational Site, Örebro, Sweden

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy